EP0906310A4 - Oxadiazol-benzosulfonamide als selektive beta-3 adrenergische rezeptor agonisten zur behandlung von diabetis und fettleibigkeit - Google Patents
Oxadiazol-benzosulfonamide als selektive beta-3 adrenergische rezeptor agonisten zur behandlung von diabetis und fettleibigkeitInfo
- Publication number
- EP0906310A4 EP0906310A4 EP97929769A EP97929769A EP0906310A4 EP 0906310 A4 EP0906310 A4 EP 0906310A4 EP 97929769 A EP97929769 A EP 97929769A EP 97929769 A EP97929769 A EP 97929769A EP 0906310 A4 EP0906310 A4 EP 0906310A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- obesity
- agonists
- diabetes
- selective
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1929596P | 1996-06-07 | 1996-06-07 | |
| US19295P | 1996-06-07 | ||
| GB9614191 | 1996-07-05 | ||
| GBGB9614191.6A GB9614191D0 (en) | 1996-07-05 | 1996-07-05 | Oxadiazole benzenesulfonamides as selectives B3 agonists for the treatment of diabetes and obesity |
| PCT/US1997/009536 WO1997046556A1 (en) | 1996-06-07 | 1997-06-03 | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0906310A1 EP0906310A1 (de) | 1999-04-07 |
| EP0906310A4 true EP0906310A4 (de) | 1999-09-01 |
Family
ID=26309646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP97929769A Ceased EP0906310A4 (de) | 1996-06-07 | 1997-06-03 | Oxadiazol-benzosulfonamide als selektive beta-3 adrenergische rezeptor agonisten zur behandlung von diabetis und fettleibigkeit |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0906310A4 (de) |
| JP (1) | JP2000511903A (de) |
| AU (1) | AU712057B2 (de) |
| CA (1) | CA2257206A1 (de) |
| WO (1) | WO1997046556A1 (de) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1743655B1 (de) | 2000-01-21 | 2014-06-25 | Novartis AG | Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica |
| US20030018061A1 (en) * | 2000-01-28 | 2003-01-23 | Kohei Ogawa | Novel remedies with the use of beta 3 agonist |
| TR200401359T4 (tr) * | 2000-03-31 | 2004-08-23 | Pfizer Products Inc. | İkame edilmiş piridinlerin hazırlanmasına yönelik işlem |
| EP1303509B1 (de) | 2000-07-13 | 2012-11-28 | Eli Lilly And Company | Beta3-adrenorezeptor agonisten |
| US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
| US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
| US6498170B2 (en) | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
| US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
| WO2002038544A2 (en) | 2000-11-10 | 2002-05-16 | Eli Lilly And Company | 3-substituted oxindole beta 3 agonists |
| AR035605A1 (es) | 2000-12-11 | 2004-06-16 | Bayer Corp | Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores |
| AR035858A1 (es) | 2001-04-23 | 2004-07-21 | Bayer Corp | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 |
| US7208505B2 (en) | 2001-08-14 | 2007-04-24 | Eli Lilly And Company | β3 adrenergic agonists |
| AU2002318206A1 (en) | 2001-08-14 | 2003-03-03 | Jolie Anne Bastian | 3-substituted oxindole beta-3 agonists |
| US6780859B2 (en) | 2001-09-14 | 2004-08-24 | Bayer Pharmaceuticals Corporation | Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists |
| WO2003044017A1 (en) | 2001-11-20 | 2003-05-30 | Eli Lilly And Company | Beta 3 adrenergic agonists |
| ATE297925T1 (de) | 2001-11-20 | 2005-07-15 | Lilly Co Eli | 3-substituierte oxindol beta 3 agonisten |
| AU2002357084A1 (en) | 2002-01-11 | 2003-07-30 | Eli Lilly And Company | 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists |
| ITMI20022389A1 (it) * | 2002-11-12 | 2004-05-13 | Nicox Sa | Farmaci per le disfunzioni sessuali. |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| HUE047569T2 (hu) | 2003-04-11 | 2020-04-28 | Ptc Therapeutics Inc | 1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása |
| JP4958560B2 (ja) * | 2003-12-24 | 2012-06-20 | プロシディオン・リミテッド | Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体 |
| EP1734963A4 (de) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen |
| EP1838706A1 (de) * | 2004-12-24 | 2007-10-03 | Prosidion Limited | Agonisten des g-protein-gekoppelten rezeptors |
| US20090325924A1 (en) * | 2005-06-30 | 2009-12-31 | Stuart Edward | GPCR Agonists |
| US20090221644A1 (en) * | 2005-06-30 | 2009-09-03 | Stuart Edward Bradley | Gpcr Agonists |
| PT1931350E (pt) | 2005-09-14 | 2014-02-12 | Takeda Pharmaceutical | Administração de inibidores de dipeptidil peptidase |
| EP1940842B1 (de) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylierte spiropiperidinderivate als modulatoren des melanocortin-4-rezeptors |
| RU2462246C2 (ru) | 2006-03-30 | 2012-09-27 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы получения функционального белка из днк, имеющей нонсенс-мутацию, и лечения нарушений, ассоциированных с ней |
| CA2657247A1 (en) | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| US8173629B2 (en) | 2006-09-22 | 2012-05-08 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US7928123B2 (en) | 2006-09-25 | 2011-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| WO2008098025A1 (en) * | 2007-02-08 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Arylsulfonamide compounds which modulate the cb2 receptor |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| US8178568B2 (en) | 2008-07-10 | 2012-05-15 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the CB2 receptor |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| CA2737639A1 (en) | 2008-09-25 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the cb2 receptor |
| EP2348857B1 (de) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Neue cyclische benzimidazolderivate als antidiabetika |
| US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| PE20120008A1 (es) | 2009-01-12 | 2012-01-24 | Icagen Inc | Derivados de fenoxi bencenosulfonamida |
| AU2010232729A1 (en) | 2009-03-31 | 2011-10-20 | Arqule, Inc. | Substituted indolo-pyridinone compounds |
| US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| JP5546543B2 (ja) * | 2009-08-05 | 2014-07-09 | 第一三共株式会社 | スルホン誘導体 |
| CN102574823B (zh) | 2009-08-05 | 2014-09-10 | 第一三共株式会社 | 酰胺衍生物 |
| WO2011037795A1 (en) | 2009-09-22 | 2011-03-31 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the cb2 receptor |
| WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| WO2011088015A1 (en) | 2010-01-15 | 2011-07-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| PL2531501T3 (pl) | 2010-02-03 | 2014-05-30 | Takeda Pharmaceuticals Co | Inhibitory kinazy 1 regulującej sygnał apoptotyczny |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| US8329735B2 (en) | 2010-03-05 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the CB2 receptor |
| JP5872552B2 (ja) | 2010-07-09 | 2016-03-01 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化学化合物 |
| WO2012012307A1 (en) | 2010-07-22 | 2012-01-26 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 rece |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| SG192941A1 (en) | 2011-02-25 | 2013-09-30 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| CA2828405A1 (en) * | 2011-02-28 | 2012-09-07 | Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale | Apoptosis-inducing molecules and uses therefor |
| PH12014500251A1 (en) | 2011-07-29 | 2014-03-17 | Daiichi Sankyo Co Ltd | N-hetero-ring-substituted amide derivative |
| RU2015106909A (ru) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | Антидиабетические трициклические соединения |
| ES2394349B1 (es) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar |
| KR20150118158A (ko) | 2013-02-22 | 2015-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 비시클릭 화합물 |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| EP2803668A1 (de) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Neuartige (Cyano-dimethyl-methyl)-isoxazole und -[1,3,4]-thiadiazole |
| BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| KR102497273B1 (ko) | 2014-03-06 | 2023-02-07 | 피티씨 테라퓨틱스, 인크. | 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염 |
| JP2018531975A (ja) | 2015-10-30 | 2018-11-01 | ピーティーシー セラピューティクス，インコーポレーテッド | てんかんの治療方法 |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298B1 (de) | 2016-12-20 | 2026-03-11 | Merck Sharp & Dohme LLC | Antidiabetische spirochromanverbindungen |
| EP4204404A4 (de) * | 2020-08-27 | 2024-12-25 | Curasen Therapeutics, Inc. | Alpha1a-adrenerge rezeptoragonisten und verfahren zur verwendung |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995029159A1 (en) * | 1994-04-26 | 1995-11-02 | Merck & Co., Inc. | SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5561142A (en) * | 1994-04-26 | 1996-10-01 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
-
1997
- 1997-06-03 WO PCT/US1997/009536 patent/WO1997046556A1/en not_active Ceased
- 1997-06-03 JP JP10500782A patent/JP2000511903A/ja active Pending
- 1997-06-03 AU AU33748/97A patent/AU712057B2/en not_active Ceased
- 1997-06-03 CA CA002257206A patent/CA2257206A1/en not_active Abandoned
- 1997-06-03 EP EP97929769A patent/EP0906310A4/de not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995029159A1 (en) * | 1994-04-26 | 1995-11-02 | Merck & Co., Inc. | SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO9746556A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU712057B2 (en) | 1999-10-28 |
| EP0906310A1 (de) | 1999-04-07 |
| JP2000511903A (ja) | 2000-09-12 |
| WO1997046556A1 (en) | 1997-12-11 |
| AU3374897A (en) | 1998-01-05 |
| CA2257206A1 (en) | 1997-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0906310A4 (de) | Oxadiazol-benzosulfonamide als selektive beta-3 adrenergische rezeptor agonisten zur behandlung von diabetis und fettleibigkeit | |
| EP0810860A4 (de) | Verfahren zur verwendung von radicicol in der behandlung von entzündungen und endotoxämie | |
| EP1014982A4 (de) | Troglitazone verbindungen zur behandlung des klimakterium | |
| EP0915847A4 (de) | Substituierte sulfonamide als selektive beta3 agonisten zur behandlung von diabetis und fettsucht | |
| GB9619331D0 (en) | Selective ›3 agonists for the treatment of diabetes and obesity | |
| FR05C0033I2 (fr) | R-enantiomere de n-propargyl-1-amino-indane pour le traitement des maladies diverses et son mesylate, esylate et sulfate | |
| DZ2675A1 (fr) | Association pharmaceutique pour le traitement d'undysfunctionnement sexuel et compositions la conte nant. | |
| OA09498A (fr) | "Utilisation du baclofène pour l'obtention de médicaments destinés au traitement de l'angine de poitrine". | |
| FR2705966B1 (fr) | Compositions antimousse utiles notamment pour le traitement de troubles gastriques. | |
| EP0689455A4 (de) | Therapeutische strategieen bei infektionen mit immuninfizierendem clustervirus | |
| FR2746658B1 (fr) | Valve de drainage implantable pour le traitement de l'hydrocephalie | |
| EP0657438A3 (de) | Verfahren zur Herstellung alkylsulfinylbenzamide und 1,2-Benzisothiazol-3-one. | |
| FR2758465B1 (fr) | Composition pour le traitement de l'amiante | |
| DZ1988A1 (fr) | Thérapie de combinaison pour le traitement de l'hiv. | |
| MA26522A1 (fr) | Composition pharmaceutique pour le traitement du diabete sucre et d'etats associes. | |
| EP0859761A4 (de) | 4-azasteroide zur behandlung von hyperandrogenen zuständen | |
| MA23837A1 (fr) | Benzamides pour le traitement de degenerescenses neurologiques | |
| FR2718024B1 (fr) | Médicament et composition pharmaceutique pour le traitement de l'inflammation. | |
| FR2728161B1 (fr) | Dispositif d'orthese pour le traitement de l'hallux valgus | |
| EP0969852A4 (de) | Kombinationstherapie zur behandlung von diabetes und fettsucht | |
| EP0800396A4 (de) | Behandlung hyperandrogener zustände | |
| FR2759906B1 (fr) | Utilisation de milnacipran et de ses derives pour la preparation d'un medicament destine au traitement de certaines maladies psychiatriques | |
| EP0687470A3 (de) | Verbindungen zur Behandlung von metabolischen Knochenkrankheiten | |
| FR2735462B1 (fr) | Dispositif pour le traitement de l'eau d'une piscine, notamment pour la desinfection de l'eau | |
| FR2759290B1 (fr) | Minalcipran pour le traitement de l'incontinence urinaire |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19990107 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
| RIC1 | Information provided on ipc code assigned before grant |
Free format text: 6C 07D 413/12 A, 6C 07D 413/14 B, 6A 61K 31/47 B, 6A 61K 31/44 B |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 19990720 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
| RTI1 | Title (correction) |
Free format text: OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE BETA-3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
|
| 17Q | First examination report despatched |
Effective date: 20000522 |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
| 18R | Application refused |
Effective date: 20010804 |